TyraTech
<< < > >>
Search:
 
| Full PDF report | Print this page |
Annual Report & Accounts 2010 - Directors' Report
slide
<< < > >>
Directors' Report The Directors present their report and the audited financial statements of TyraTech, Inc. for the year ended December 31, 2010. Results and Divid ends The net loss for the year, after taxation, amounted to US $6.1 million against a net loss of US $13.9 million in 2009. No dividends have been declared or paid. Pri ncip al Acti viti es The principal activity of the Group is the development and commercializing of proprietary insecticide and parasiticide products which incorporate unique blends of natural, plant oil derived active ingredients. Business Review A review of the Group's operations during the year, and the outlook for the future are given in the Executive Chairman's Review on page 6. A discussion of the principal risks and uncertainties facing the Company is set out below. Where the Directors' Report (including the Executive Chairman's Statement and Financial Review) contains forwardlooking statements, these are made by the Directors in good faith based on the information available to them at the time of the approval of this report. Consequently, such statements should be treated with caution due to their inherent uncertainties, including both economic and business risk factors, underlying such forward-looking statements or information. Research and Development The Directors believe that research and product development play a vital role in the Group's long-term success. Research and development expenditure is expensed when incurred and for the year was US $3.1 million (2009: US $4.4 million). Intellectual Propert y The Group owns intellectual property and has taken steps to protect this through patent applications, where, as of the date of this report, 11 patents were issued (2009: 11) and 61 patents are pending (2009: 119). The Group's key intellectual property is built around the screening methods for identifying active ingredients for synergistic receptor activation and the active ingredient combinations. The Directors believe that the intellectual property is of significant value to the business. Supp lier Payment Policy The Group's policy is to settle the terms of payment with suppliers when agreeing to the terms of each transaction, or the terms of a continuing trading relationship, ensuring that suppliers are made aware of the terms of payment, and to abide by these terms whenever possible. The creditor days at the year-end were 51 days (2009: 66 days) for the Group. Equal Opp ort unit y Employer The Group is committed to a policy that provides all employees and potential employees with equality of opportunity for selection and development regardless of age, gender, nationality, race, creed, disability or sexual orientation. At the 31 December 2010 the Group had 16 employees (2009: 31 employees). Policy on Employee Involvement Briefing and consultative procedures exist throughout the Group to keep employees informed of general business issues and other matters of concern. Safety, health and envir onment The Group is committed to maintaining high standards of safety, health and environmental protection by conducting itself in a responsible manner to protect people and the environment. Pri ncip al ri sks and uncert ainti es The management of the business and the nature of the Group's strategy are subject to a number of risks and uncertainties. The Directors have set out below principal risks facing the business: 14